论文部分内容阅读
目的观察顺铂联合吉西他滨治疗晚期非小细胞肺癌(NSCLC)的疗效与不良反应。方法 32例NSCLC患者,均接受顺铂联合吉西他滨的化疗方案进行治疗,观察患者临床疗效、生活质量及不良反应情况。结果 32例患者均可评价疗效与药物不良反应。治疗总有效率为50.00%,临床获益率为68.75%。56.25%的患者生活质量得到提高,不良反应主要为轻度白细胞减少及血小板减少,发生率分别为40.63%和37.50%。结论顺铂联合吉西他滨治疗晚期NSCLC疗效确切,可改善患者的生活质量,不良反应轻微,安全性较好,值得临床推广应用。
Objective To observe the efficacy and side effects of cisplatin and gemcitabine in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Thirty-two patients with NSCLC received cisplatin and gemcitabine chemotherapy. The clinical efficacy, quality of life and adverse reactions were observed. Results 32 patients can evaluate the efficacy and adverse drug reactions. The total effective rate was 50.00%, the clinical benefit rate was 68.75%. The quality of life of 56.25% patients was improved, the main adverse reactions were mild leukopenia and thrombocytopenia, the incidence rates were 40.63% and 37.50% respectively. Conclusion Cisplatin combined with gemcitabine in the treatment of advanced NSCLC is effective and can improve the quality of life of patients with mild adverse reactions and good safety, which is worthy of clinical application.